Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray
Completed · Phase 4 · NCT05514041
Conditions: Dry Eye Disease
At a glance
- Research payments reported, 2025
- $22,500
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- Stephenson Eye Associates
- Tested
- Varenicline solution (drug), Placebo nasal spray (OC-01 Vehicle Nasal Spray) (drug)
- Dates
- Started 2022-10-11; completion 2023-12-05
- Results posted
- Not yet
A randomized, controlled, double-masked, investigator-initiated trial to evaluate tear film quality and stability in subjects with dry eye disease using OC-01 (varenicline solution) nasal spray 0.03 mg as compared to vehicle control nasal spray.
From ClinicalTrials.gov, last updated 2026-05-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Oyster Point Pharma, Inc. reported $22,500 in research payments for this study in 2025 (1 payments).
Products named: Tyrvaya
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Stephenson Eye Associates $22,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.